Department of Plant & Microbial Biology, University of California, Berkeley, Berkeley, California, USA.
Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
mBio. 2020 Dec 8;11(6):e02507-20. doi: 10.1128/mBio.02507-20.
The beneficial human gut bacterium provides metabolites to other members of the gut microbiota by breaking down host mucin, but most of its other metabolic functions have not been investigated. strain Muc is known to use cobamides, the vitamin B family of cofactors with structural diversity in the lower ligand. However, Muc is unable to synthesize cobamides , and the specific forms that can be used by have not been examined. We found that the levels of growth of Muc were nearly identical with each of seven cobamides tested, in contrast to nearly all bacteria that had been studied previously. Unexpectedly, this promiscuity is due to cobamide remodeling-the removal and replacement of the lower ligand-despite the absence of the canonical remodeling enzyme CbiZ in We identified a novel enzyme, CbiR, that is capable of initiating the remodeling process by hydrolyzing the phosphoribosyl bond in the nucleotide loop of cobamides. CbiR does not share similarity with other cobamide remodeling enzymes or B-binding domains and is instead a member of the apurinic/apyrimidinic (AP) endonuclease 2 enzyme superfamily. We speculate that CbiR enables bacteria to repurpose cobamides that they cannot otherwise use in order to grow under cobamide-requiring conditions; this function was confirmed by heterologous expression of in Homologs of CbiR are found in over 200 microbial taxa across 22 phyla, suggesting that many bacteria may use CbiR to gain access to the diverse cobamides present in their environment. Cobamides, comprising the vitamin B family of cobalt-containing cofactors, are required for metabolism in all domains of life, including most bacteria. Cobamides have structural variability in the lower ligand, and selectivity for particular cobamides has been observed in most organisms studied to date. Here, we discovered that the beneficial human gut bacterium can use a diverse range of cobamides due to its ability to change the cobamide structure via a process termed cobamide remodeling. We identify and characterize the novel enzyme CbiR that is necessary for initiating the cobamide remodeling process. The discovery of this enzyme has implications for understanding the ecological role of in the gut and the functions of other bacteria that produce this enzyme.
有益的人类肠道细菌通过分解宿主粘蛋白为其他肠道微生物群成员提供代谢物,但它的其他大多数代谢功能尚未被研究。已知菌株 Muc 能够使用钴胺素,即结构多样性的维生素 B 族辅酶,在较低配体中。然而,Muc 不能合成钴胺素,并且尚未检查可以使用的特定形式。我们发现,在所测试的七种钴胺素中,每种钴胺素的生长水平与 Muc 几乎相同,这与以前研究过的几乎所有细菌都不同。出乎意料的是,这种混杂性是由于钴胺素重塑——去除和替换较低的配体——尽管在 Muc 中不存在典型的重塑酶 CbiZ。我们鉴定了一种新型酶 CbiR,它能够通过水解钴胺素核苷酸环中的磷酸核糖基键来启动重塑过程。CbiR 与其他钴胺素重塑酶或 B 结合结构域没有相似性,而是属于脱嘌呤/脱嘧啶(AP)内切酶 2 酶超家族的成员。我们推测,CbiR 使细菌能够重新利用它们在其他情况下无法使用的钴胺素,以便在需要钴胺素的条件下生长;这一功能通过在 中异源表达 得到了证实。CbiR 的同源物存在于超过 200 个微生物分类群中,跨越 22 个门,这表明许多细菌可能使用 CbiR 来获得其环境中存在的各种钴胺素。钴胺素,包括含钴维生素 B 族辅酶,是所有生命领域代谢所必需的,包括大多数细菌。钴胺素在较低配体中有结构变异性,并且迄今为止在大多数研究过的生物体中都观察到对特定钴胺素的选择性。在这里,我们发现有益的人类肠道细菌 可以使用广泛的钴胺素,因为它能够通过一种称为钴胺素重塑的过程改变钴胺素的结构。我们鉴定并表征了启动钴胺素重塑过程所必需的新型酶 CbiR。这种酶的发现对于理解 在肠道中的生态作用以及产生这种酶的其他细菌的功能具有重要意义。